Search results
Results From The WOW.Com Content Network
Iodine-131 (131 I, I-131) is an important radioisotope of iodine discovered by Glenn Seaborg and John Livingood in 1938 at the University of California, Berkeley. [3] It has a radioactive decay half-life of about eight days. It is associated with nuclear energy, medical diagnostic and treatment procedures, and natural gas production.
Due to similar destruction, 131 I is the iodine radioisotope used in other water-soluble iodine-labeled radiopharmaceuticals (such as MIBG) used therapeutically to destroy tissues. The high energy beta radiation (up to 606 keV) from 131 I causes it to be the most carcinogenic of the iodine isotopes.
[1] [2] When the iodine atom is a radioactive isotope (iodine-125 or iodine-131), it is used as an adrenal cortex radiotracer in the diagnosis of patients suspected of having Cushing's syndrome, hyperaldosteronism, [3] pheochromocytoma, and adrenal remnants following total adrenalectomy. [1] [2]
This is an accepted version of this page This is the latest accepted revision, reviewed on 25 February 2025. This article is about the chemical element. For other uses, see Iodine (disambiguation). Chemical element with atomic number 53 (I) Iodine, 53 I Iodine Pronunciation / ˈ aɪ ə d aɪ n, - d ɪ n, - d iː n / (EYE -ə-dyne, -din, -deen) Appearance lustrous metallic gray solid ...
This page lists radioactive nuclides by their half-life.
Product labeling for diagnostic 131 I iobenguane recommends giving potassium iodide one day before injection and continuing 5 to 7 days following. [ 19 ] 131 I iobenguane used for therapeutic purposes requires a different pre-medication duration, beginning 24–48 hours before iobenguane injection and continuing 10–15 days after injection.
Tositumomab is a murine monoclonal antibody which targets the CD20 antigen produced in mammalian cell. [1] It was combined with iodine-131 to produce a radiopharmaceutical for unsealed source radiotherapy, Iodine-131 Tositumomab (branded as Bexxar), for the treatment of non-Hodgkins lymphoma. [1]
Iodine-131 (131 I) is the most common RNT worldwide and uses the simple compound sodium iodide with a radioactive isotope of iodine. The patient (human or animal) may ingest an oral solid or liquid amount or receive an intravenous injection of a solution of the compound. The iodide ion is selectively taken up by the thyroid gland.